Roche wades deeper into the allogeneic CAR-T field, reserving billions for its next early-stage partner

John Carroll

Editor & Founder

Aayushi Pratap

News Reporter

Roche has taken its next big step into the allogeneic CAR-T field, this time tying up alongside Poseida Therapeutics $PSTX with $220 million in upfront …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Roche wades deeper into the allogeneic CAR-T field, reserving billions for its next early-stage partner

John Carroll

Editor & Founder

Aayushi Pratap

News Reporter

Sign up to read this article for free.

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

Updated: Novo’s 23% weight loss with CagriSema falls short of high expectations, new trial planned

FDA approves Humacyte’s lab-grown blood vessels in milestone for regenerative medicine

Exclusive: Florida cancer biotech raises $100M Series A

Accelerated approval brings Pfizer's BRAF inhibitor to first-line patients

Califf, on his way out at FDA, predicts agency tug-of-war between Ramaswamy and RFK Jr.

Roche wades deep­er in­to the al­lo­gene­ic CAR-T field, re­serv­ing bil­lions for its next ear­ly-stage part­ner

Editor & Founder

News Reporter

Sign up to read this article for free.

more like this

Roche wades deeper into the allogeneic CAR-T field, reserving billions for its next early-stage partner